Candel Therapeutics (CADL) Preferred Stock Liabilities (2020 - 2021)
Candel Therapeutics recorded quarterly Preferred Stock Liabilities of $22.5 million in Q2 2021, down 15.29% quarter-over-quarter from $26.6 million in Q1 2021, and little changed year-over-year from $22.5 million in Q2 2020.
Candel Therapeutics' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $22.5 million for Q2 2021.
- In Q2 2021, Preferred Stock Liabilities changed 0.0% year-over-year to $22.5 million; the TTM figure through Jun 2021 stood at $22.5 million (changed 0.0% YoY), while the FY2020 annual figure was $22.5 million, changed N/A from the prior year.
- Preferred Stock Liabilities came in at $22.5 million for Q2 2021 at Candel Therapeutics, down from $26.6 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $26.6 million in Q3 2020 to a low of $22.5 million in Q2 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Candel Therapeutics | 449.62 Mn | 449.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 22.50 Mn |
| Mar 31, 2021 | 26.56 Mn |
| Dec 31, 2020 | 22.50 Mn |
| Sep 30, 2020 | 26.56 Mn |
| Jun 30, 2020 | 22.50 Mn |